Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

  • STATUS
    Recruiting
  • participants needed
    56
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Updated on 28 September 2022

Summary

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or radiation.

Details
Condition Advanced Cutaneous Squamous Cell Carcinoma
Treatment IBI318
Clinical Study IdentifierNCT04611321
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on28 September 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note